Setting Up a Pharmaceutical Import and Re-Export Business in the UAE: The Complete Guide

V-Sentinel Editorial · Healthcare supply chain market entry, UAE & GCC

---

The UAE has become the default staging post for pharmaceutical companies moving product into the Gulf, Africa, and the wider region. The reasons are structural: a bonded free-zone system built for re-export, air and sea links that reach a large share of the world's population within hours, and a federal drug regulator consolidating what used to be a fragmented approvals landscape. Jebel Ali Free Zone alone now hosts more than 400 healthcare and pharmaceutical companies from around 60 countries, including the regional headquarters of Roche, Sanofi, Johnson & Johnson, and GSK.¹

The gap between "the UAE is a good idea" and a licensed, inspection-ready operation shipping its first pallet is wide, and it is where most new entrants lose months. The decisions stack on each other: the structure you choose constrains your warehousing options, your warehousing choice changes your licensing path, and your licensing sequence determines when — and whether — product can move. This guide walks the whole journey in the order the decisions actually arrive: structure, facility, approvals, and flow. It is the long-form companion to our Market Entry roadmap, written for the two situations we most often see — a company setting up a UAE distribution business for the first time, and one that wants to use the UAE as an import and re-export hub.

A note before we start: what follows is orientation, not a regulatory determination. The specific free zone, licence category, and approvals that apply to you depend on your products, your markets, and your documents. Treat this as the map, not the turn-by-turn.

1. Structure — free zone, mainland, or both

The first decision shapes everything after it, and it turns on one question: who are you selling to?

A free zone establishment gives you full foreign ownership and a bonded environment purpose-built for import and re-export. You can bring product into the zone, hold it, and ship it on to international markets at zero customs duty, with no local partner required.² For a re-export hub, this is precisely the point. What a free-zone entity cannot do is invoice a customer on the UAE mainland directly. To serve the domestic market, a free-zone company either clears goods through customs — paying the applicable duty — or appoints a licensed mainland distributor who buys from the zone and resells locally.²

A mainland licence is the mirror image: unrestricted access to UAE customers, hospital tenders, and pharmacies, but without the bonded re-export machinery and under local ownership and licensing rules that differ by activity.

Most operators do not actually face an either/or. A company using the UAE as a regional hub runs a free-zone entity to hold and re-export stock; a company that also wants the local market adds a mainland route — its own licence or a distributor relationship — for domestic sales. Getting this combination right at the start avoids an expensive restructure once volumes arrive.

Which free zone? For pharmaceuticals the shortlist is shorter than the UAE's forty-plus zones suggest, because you need one set up for regulated healthcare storage. Jebel Ali Free Zone (JAFZA) is the established heavyweight, with temperature-controlled warehousing, a bonded re-export model, and the deepest cluster of healthcare tenants.¹ Dubai Science Park is the region's dedicated life-sciences free zone, oriented to pharmaceutical and medical companies.³ In Abu Dhabi, KEZAD (Khalifa Economic Zones Abu Dhabi) has been building a healthcare and manufacturing cluster — part of the broader Gulf manufacturing corridor.³ Airport-adjacent zones suit fast-moving, air-freighted cold-chain product. The right choice depends on your product's temperature profile, your inbound and outbound lanes, and whether you will ever manufacture or repackage — which is exactly the analysis to do before you sign, not after.

2. Facility — your own warehouse, or a 3PL

Once the structure is set, the next decision most shapes your cost and speed to market: do you build and license your own warehouse, or outsource to a third-party logistics (3PL) provider?

Either way, the storage itself has to be GDP-licensed — in UAE terms, it needs the Certificate of Distribution and Good Storage the regulator requires for a medical warehouse, with validated temperature control, monitoring, and documentation.⁴ The question is who holds that licence and runs that facility.

Running your own warehouse gives you control over the facility, the staff, and the process, and at high, predictable volumes the unit economics can beat a 3PL's rate. The costs are capital, time, and burden: fitting out and validating a compliant temperature-controlled facility, licensing it in your own name, and standing up qualified operations — a Responsible Person, SOPs, training records, monitoring — from day one.

Outsourcing to a GDP-licensed 3PL inverts that. You launch from a facility that is already built and already inspected, convert a large fixed cost into a per-unit variable one, and reach your first shipment far faster. You give up some control and some margin at scale.

There is no universal answer — only the right one for your volumes, product mix, and timeline. As a rough guide: high, predictable volume and a long-term UAE base lean towards an own facility; early-stage, seasonal, or hard-to-forecast volume and a tight timeline lean towards a 3PL. Most new entrants launch through a 3PL and revisit the own-facility question once volumes are proven. We expand this trade-off, with the decision framework, in the own-warehouse-versus-3PL section of our Market Entry guide. Whichever route you choose, the facility will be judged against the same eight domains a GDP inspection examines, so it has to be built to that standard from the outset.

3. Approvals — the EDE licensing roadmap

Since the end of 2025, the approvals that used to sit with MOHAP's drug department now run through the Emirates Drug Establishment (EDE), the federal authority that assumed 44 pharmaceutical services — establishment licensing, import and export permits, GMP certification, and product marketing authorisation among them — effective 29 December 2025, all submitted through the EDE portal.⁵ We covered that transition and what it changed for existing establishments in a separate article; here the focus is the sequence a new entrant follows.

The approvals stack in a dependent order, and planning that order is where time is won or lost:

• Establishment / facility licence — your pharmaceutical warehouse or medical store must be licensed as an establishment, which is where the Good Storage and Distribution certificate is assessed.⁵⁴
• Import and export permits — the authorisations that let product cross the border into and out of your operation.⁵
• GMP recognition — for the manufacturers whose products you carry, evidence of Good Manufacturing Practice acceptable to the EDE.⁵
• Product / marketing authorisation — each product placed on the market generally needs to be registered; re-export-only flows differ from products entering the local market.
• Responsible Person — a qualified individual of record, named on the licence and accountable for quality.

The trap is treating these as a checklist rather than a critical path. A licence application that depends on a facility not yet fitted out, or an import permit that assumes a product registration still in the queue, stalls the whole line. Sequencing the filings so each prerequisite is ready when the next stage needs it is the single highest-leverage piece of planning in the entire setup.

4. The flow — running the UAE as a re-export hub

With structure, facility, and approvals in place, the operation itself is the bonded import-store-re-export cycle the free zone is built for. Product arrives into the zone under bond, is held compliantly, and is re-exported to its destination markets — with no customs duty on the intermediary steps.⁶ JAFZA's leading re-export destinations run across the Gulf and into markets such as Iraq, Kuwait, Jordan, and Yemen, with African and wider routes layered on top.⁶

Two things separate a hub that flows from a warehouse where consignments sit.

The first is documentation discipline. Each destination regulator expects its own paperwork — import permits, certificates of origin, batch records and, for medicines, temperature records. The re-export leg is only as fast as the documents that accompany it; a missing certificate is what turns a two-day transhipment into a two-week hold.

The second is cold chain across borders. If you handle refrigerated (2–8°C) or ambient (15–25°C) product, the temperature control validated in your warehouse has to hold through every onward leg, in a climate that is actively hostile to it. Our guide to cold chain storage requirements in the UAE covers what that takes. Layered on top is Tatmeen, the UAE's GS1-aligned serialisation platform, which requires commissioning and aggregation for covered products — a digital trail that has to be right from the first shipment, not reconstructed later.⁷

Sequencing it — the order that saves months

The through-line of this guide is that the four areas are not independent. The most common — and most expensive — mistake is doing them in isolation: signing a free-zone lease before the licensing implications are understood, or committing to an own warehouse on a timeline only a 3PL can meet. The work that pays for itself is sequencing them as one plan, so structure, facility, approvals, and flow line up instead of contradicting each other.

That is the point of the Market Entry roadmap: the same four stages, laid out in order, with a short setup diagnostic that turns your product type, markets, and timeline into an indicative route. If you are weighing the UAE as a base — or you have committed and want the sequence built properly — that is the place to start.

Footnotes

1. Jebel Ali Free Zone (Jafza), Healthcare & Pharmaceutical industry at Jafza and Jafza's healthcare companies spur seven-fold growth in trade value in four years — Jafza reports hosting more than 400 healthcare and pharmaceutical companies from around 60 countries, including regional headquarters of Roche, Sanofi, Johnson & Johnson and GSK, with temperature-controlled and bonded warehousing. jafza.ae. ↩ ↩²

2. Comparative analyses of UAE free zone versus mainland company licences — a free-zone entity may import and re-export internationally at 0% customs duty but cannot invoice mainland UAE customers directly; to reach the domestic market it clears goods through customs or appoints a licensed mainland distributor. Global Law Experts; Decisive Zone. Exact treatment depends on the activity and the licensing authority. ↩ ↩²

3. Dubai Science Park, Healthcare and Life Sciences Hub (a TECOM Group free zone focused on pharmaceutical and life-science businesses), dsp.ae; Khalifa Economic Zones Abu Dhabi (KEZAD) healthcare and life-sciences cluster, as reflected in LIFEPharma's KEZAD manufacturing platform announced at Make It in the Emirates 2026. dsp.ae / gulfnews.com. ↩ ↩²

4. Ministry of Health and Prevention (UAE), Licensing of a Pharmaceutical Facility — the Good Practice certificates required for licensing include the Certificate of Distribution and Good Storage for medical warehouses; foundational framework under Federal Law No. 4 of 1983 concerning the pharmacy profession and pharmaceutical institutions. mohap.gov.ae. ↩ ↩²

5. Ministry of Health and Prevention (UAE), MOHAP announces the transfer of selected services to the Emirates Drug Establishment — 44 services, including marketing authorisations, import and export permits, GMP certification and pharmaceutical facility licensing (factories, warehouses, medical stores and marketing offices), transferred to the EDE effective 29 December 2025 and submitted through the EDE portal. mohap.gov.ae/en/mte; Emirates Drug Establishment, Services, ede.gov.ae. ↩ ↩² ↩³ ↩⁴

6. Jebel Ali Free Zone (Jafza) — bonded warehouse and re-export model: goods can be imported into the zone, stored or repackaged, and re-exported without customs duty on the intermediary steps; leading regional re-export markets include Iraq, Kuwait, Jordan and Yemen. jafza.ae, and general UAE bonded-warehouse and re-export practice. ↩ ↩²

7. Ministry of Health and Prevention (UAE), Tatmeen — National Track and Trace Platform for Medicinal Products (GS1-aligned serialisation; commissioning and aggregation required for covered products), mohap.gov.ae/tatmeen. ↩